Prevention of Arrhythmia Device Infection Trial (PADIT Pilot) (PADIT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01002911 |
Recruitment Status
:
Completed
First Posted
: October 28, 2009
Last Update Posted
: May 16, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Arrythmias | Drug: Cefazolin, Bacitracin, Cefalexin Drug: Cefazolin | Phase 3 |
Infection can occur after surgery for either a pacemaker or an implantable defibrillation and can have very serious consequences. These infections are common and can be seen in as many as 2-3% of high-risk patients. Doctors use antibiotics to prevent these infections, but we do not know how much or how often to give the antibiotics to get the best effect. It is not known whether additional antibiotics during and after the operation would further reduce the risk of infection. This research study will compare two different ways of using common antibiotics to prevent infection during and following a device procedure. One way is the standard approach of a single dose before surgery and the other way uses more antibiotics. We do not know if either way is better. The purpose of this study therefore, is to compare two types of antibiotic therapy plans to better understand if one is most effective in preventing infection.
This study will provide the ability to evaluate the feasibility (i.e. site activation, enrollment, compliance, drop-out) and generate proof of concept for the larger clinical trial of 12,000 patients in all 25 Canadian Hospitals implanting ICDs, which will be submitted to the CIHR. Additionally, the study supports the continued initiatives of the network of physician investigators (Canadian Heart Rhythm Society Device Advisory Committee - CHRS DAC) collaborating to address arrhythmia procedures related clinical trials that will answer simple clinical questions that will focus initially on safety issues.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 500 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Phase III Pilot Study - A Simple Randomized Trial of Conventional Versus Multimodal Prevention of Arrhythmia Device Infection |
Study Start Date : | December 2009 |
Actual Primary Completion Date : | January 2012 |
Actual Study Completion Date : | January 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: Aggressive Antibiotic therapy
Patients receive preoperative intravenous antibiotics, intracavitary antibiotics during surgery and postoperative antibiotics.
|
Drug: Cefazolin, Bacitracin, Cefalexin
Single does of Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision, Bacitracin wash, Cefalexin 250-500 mg TID
|
Active Comparator: Conventional Antibiotic Therapy
Preoperative intravenous antibiotics
|
Drug: Cefazolin
Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision
|
- Hospitalization attributed to device infection. [ Time Frame: Patients will have one follow-up visit at 12 months or earlier should a primary outcome event occur. ]
- 1. Any treatment with antibiotics for suspected device infection. [ Time Frame: Patients will have one follow-up visit at 12 months ]
- 2. Antibiotic therapy related adverse event. [ Time Frame: Patients will have one follow-up visit at 12 months ]
- 3. Prolongation of hospitalization due to proven or suspected adverse events from the hospitalization. [ Time Frame: Patients will have one follow-up visit at 12 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- > 18 years
-
One of the following planned device procedures:
- ICD, pacemaker, CRT-P, CRT-D generator and/or lead replacement or
- Pocket or lead revision or
- System upgrade (insertion or attempted insertion of leads) or
- New cardiac resynchronization therapy device implant (pacemaker or ICD)
Exclusion Criteria:
- Unable or unwilling to provide written informed consent
- Unable or unwilling to complete the study follow-up schedule
- Life expectancy < 12 months as per the opinion if the local investigator
- Allergy to or unable to tolerate cefazolin or clindamycin or vancomycin
- Allergy to or unable to tolerate intracavitary bacitracin or gentamicin or cefazolin
- Previously enrolled in this trial
- In another study that would confound the results of this trial

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01002911
Canada, Quebec | |
Institut universitaire de cardiologie et de pneumologie de Quebec | |
Ste-Foy, Quebec, Canada, G1V 4G5 |
Principal Investigator: | Dr. Andrew Krahn | University of British Columbia |
Responsible Party: | Population Health Research Institute |
ClinicalTrials.gov Identifier: | NCT01002911 History of Changes |
Other Study ID Numbers: |
PADIT |
First Posted: | October 28, 2009 Key Record Dates |
Last Update Posted: | May 16, 2013 |
Last Verified: | May 2013 |
Keywords provided by Population Health Research Institute:
Device procedure pacemaker ICD antibiotics |
Additional relevant MeSH terms:
Anti-Bacterial Agents Cefazolin Cephalexin Bacitracin |
Antibiotics, Antitubercular Anti-Infective Agents Antitubercular Agents Anti-Infective Agents, Local |